Neogenomics (NEO) Long-Term Investments (2020 - 2021)

Neogenomics' (NEO) quarterly Long-Term Investments came in at $29.6 million in Q1 2021, little changed on a QoQ basis from $29.6 million in Q4 2020.

Neogenomics (NEO) Long-Term Investments (2020 - 2021) Analysis & Trends

Neogenomics (NEO) has 2 years of Long-Term Investments data on file, last reported at $29.6 million in Q1 2021.

Quarterly Long-Term Investments changed N/A year-over-year to $29.6 million in Q1 2021, while the trailing twelve-month figure through Mar 2021 was $29.6 million (changed N/A YoY) and the FY2020 annual result came in at $29.6 million, changed N/A from the prior year.
Long-Term Investments was little changed at $29.6 million in Q1 2021, from $29.6 million in the prior quarter.
In the past five years, Long-Term Investments ranged from a high of $29.6 million in Q4 2020 to a low of $13.1 million in Q2 2020.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Long-Term Investments (Qtr)
1	Thermo Fisher Scientific	234.15 Bn	230.09 Bn	8.34 Bn	-
2	Danaher	152.10 Bn	147.75 Bn	3.61 Bn	-
3	Natera	48.48 Bn	47.38 Bn	486.15 Mn	-
4	Agilent Technologies	44.35 Bn	42.55 Bn	990.00 Mn	136.00 Mn
5	Iqvia Holdings	43.68 Bn	41.60 Bn	1.44 Bn	390.00 Mn
6	Idexx Laboratories	43.02 Bn	42.83 Bn	779.09 Mn	-
7	Illumina	34.39 Bn	33.22 Bn	770.00 Mn	-
8	Mettler Toledo International	28.29 Bn	28.24 Bn	650.22 Mn	-
9	Labcorp Holdings	27.51 Bn	27.37 Bn	1.11 Bn	210.00 Mn
10	Neogenomics	2.42 Bn	2.28 Bn	91.88 Mn	-

Download Data